Pretreatment with Relaxin Does Not Restore NO-Mediated Modulation of Calcium Signal in Coronary Endothelial Cells Isolated from Spontaneously Hypertensive Rats by Nistri, Silvia et al.
Molecules 2015, 20, 9524-9535; doi:10.3390/molecules20069524 
 
molecules 
ISSN 1420-3049 
www.mdpi.com/journal/molecules 
Article 
Pretreatment with Relaxin Does Not Restore NO-Mediated 
Modulation of Calcium Signal in Coronary Endothelial Cells 
Isolated from Spontaneously Hypertensive Rats 
Silvia Nistri 1, Lorenzo Di Cesare Mannelli 2, Carla Ghelardini 2, Matteo Zanardelli 2,  
Daniele Bani 1 and Paola Failli 2,* 
1 Departments of Clinical & Experimental Medicine, Research Unit of Histology & Embryology 
University of Florence, Viale G. Pieraccini 6, 50139 Florence, Italy;  
E-Mails: silvia.nistri@unifi.it (S.N.); daniele.bani@unifi.it (D.B.) 
2 NEUROFARBA, Section of Pharmacology & Toxicology, University of Florence,  
Viale G. Pieraccini 6, 50139 Florence, Italy; E-Mails: lorenzo.mannelli@unifi.it (L.D.C.M.); 
carla.ghelardini@unifi.it (C.G.); mattezana.mz@gmail.com (M.Z.) 
* Author to whom correspondence should be addressed; E-Mail: paola.failli@unifi.it. 
Academic Editor: Claudio Battilocchio 
Received: 18 March 2015 / Accepted: 15 May 2015 / Published: 26 May 2015 
 
Abstract: We demonstrated that in coronary endothelial cells (RCEs) from normotensive 
Wistar Kyoto rats (WKY), the hormone relaxin (RLX) increases NO production and reduces 
calcium transients by a NO-related mechanism. Since an impairment of the NO pathway has 
been described in spontaneously hypertensive rats (SHR), the present study was aimed at 
exploring RLX effects on RCEs from SHR, hypothesizing that RLX could restore calcium 
responsiveness to NO. RCEs were isolated from WKY and SHR. Calcium transients were 
evaluated by image analysis after the administration of angiotensin II or α-thrombin. 
Angiotensin II (1 µM) caused a prompt rise of [Ca2+]i in WKY and SHR RCEs and a rapid 
decrease, being the decay time higher in SHR than in WKY. NOS inhibition increased 
calcium transient in WKY, but not in SHR RCEs. Whereas RLX pretreatment (24 h, 60 ng/mL) 
was ineffective in SHR, it strongly reduced calcium transient in WKY in a NO-dependent 
way. A similar behavior was measured using 30 U/mL α-thrombin. The current study offers 
evidence that RLX cannot restore NO responsiveness in SHR, suggesting an accurate 
selection of patients eligible for RLX treatment of cardiovascular diseases. 
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1. Introduction 
In the vascular system, the nitric oxide (NO) pathway mediates vasorelaxation and platelet  
anti-aggregation and protects from ischemic disorders [1]. NO, physiologically produced by different 
nitric oxide synthase isoforms (eNOS, nNOS and iNOS), can activate soluble guanylyl cyclase (sGC) to 
produce cyclic guanosine monophosphate (cGMP), which in turn activates the cGMP-dependent protein 
kinase (cGK-I), modulating ion channels, phosphodiesterases and calcium pumps [2]. In this context, 
convincing evidences exist in the literature that the hormone relaxin (RLX) can promote coronary and 
systemic vasodilatation by increasing NO bioavailability and NOS enzyme expression [3], thereby 
reducing hypertension and protecting the heart against ischemia/reperfusion-induced injury [4,5]. Thus, 
administration of recombinant human H2 RLX, or serelaxin, has been proposed as a potential therapeutic 
strategy for hypertension and heart ischemia [6]. 
The spontaneously hypertensive rat (SHR) is an animal model used for the study of hypertension, 
hypertensive heart disease, cardiac remodeling and hypertrophy. In this model, alterations in Ca2+ 
handling have been described at very early stages of the disease, even before the appearance of cardiac 
remodeling [7]. Many different factors are involved in this spontaneous, age-dependent pathological 
condition, including an impairment of the NO pathway. In particular: (i) mRNA expression of  
cGMP-dependent protein kinase I (cGKI) was found reduced in aortic rings of 6 week-old SHR [8]; (ii) 
decreased cGK activity was detected in ventricular and atrial tissue of aged SHR [9] and other forms of 
hypertensive animals [10] and (iii) and, according to our research data, the cGKI expression is reduced 
in cardiomyocytes and coronary endothelial cells (RCEs) of 12 week old SHR [11,12]. Of note, cGKI is 
a major regulator of intracellular calcium homeostasis and its over-expression was found to restore  
NO-mediated calcium regulation in RCEs and aortic smooth muscle cells isolated from SHR [12,13].  
Along this line of thought, the administration of RLX to in female non-pregnant SHR was reported 
to cause a sustained decrease in blood pressure [14] and to substantially blunt the vascular response to 
vasoconstrictors in mesenteric vasculature but not in portal vein [15]. Besides these acute functional 
effects, RLX was also capable of reverting arterial adverse remodeling and decreased compliance in 
elderly SHR [16]. 
The cellular mechanisms underlying these vascular effects of RLX are not fully understood but 
represent a topic worthy of investigation because of their obvious medical interest. In this context, 
previous studies performed by our team on RCEs from Wistar Kyoto (WKY) rats, the normotensive 
counterpart of SHR, have demonstrated that RLX increases NO production by up-regulating NOS 
expression and decreases vasoconstrictor-induced intracellular calcium concentration ([Ca2+]i) rise by a 
NO-related mechanism [17]. Therefore, it was reasonable to assume that a similar mechanisms may also 
be operating in SHR.  
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In the present study we aimed at exploring the effects of RLX on RCEs isolated from SHR, based on 
the working hypothesis that RLX may restore [Ca2+]i responsiveness to NO. According to our previous 
study on WKY and SHR, we used angiotensin II (AT-II) and α-thrombin (THR) to induce [Ca2+]i 
increase in RCEs, since these cells have been shown to express AT-II and THR receptors and to respond 
to exogenous AT-II and THR by modulation of NO-dependent [Ca2+]i increase [12,18,19]. Preliminary 
data were presented at the Fourth International Conference on “Relaxin and related peptides” [20]. 
2. Results 
2.1. Intracellular Ca2+ Control Conditions 
At baseline, [Ca2+]i, evaluated by Fura 2 fluorescence, was 112.5 ± 2.76 nM in RCEs isolated from 
WKY and slightly higher in those from SHR (144.1 ± 7.43 nM). Stimulation of RCEs with 1 µM  
AT-II, caused a prompt rise of [Ca2+]i in both WKY and SHR strains (Figure 1).  
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Figure 1. Evaluation of [Ca2+]i. in RCE isolated from WKY and SHR rats.  
(A) Representative tracings of [Ca2+]i-associated fluorescence in Fura-2 RCEs from WKY 
rats in control and RLX-pretreated cultures upon challenge with AT-II; (B) Representative 
tracings of [Ca2+]i-associated fluorescence in Fura 2-loaded RCEs from SHR in control and 
RLX-pretreated cultures upon challenge with AT-II. AT-II (1 μM) was added at the arrow 
(time = 0) and maintained throughout the experiment, as indicated. Cells were incubated for 
24 h in serum-free medium in the absence (controls) or presence of 60 ng/mL RLX. 
In the SHR cells, the maximum [Ca2+]i increase was slightly, albeit not significantly higher than in 
those from WKY (Figure 2A). Calcium signals decreased rapidly in WKY RCEs with a decay time of 
19.2 ± 0.61 s, whereas in SHR cells, the decay time was significantly higher (Figure 2B). A 10 min. 
incubation with the NO-donor SNAP significantly decreased maximum [Ca2+]i increase and decay time 
in the WKY cells, whereas it was ineffective in the SHR RCEs (Figure 2). Moreover, 20 min. 
preincubation with the non-selective NOS inhibitor L-NAME significantly increased maximum [Ca2+]i 
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increase and decay time in the WKY, but not in the SHR cells. Inhibition of NOS II with W1400 had no 
effect on calcium transient in both strains.  
 
Figure 2. Evaluation of [Ca2+]i in RCE isolated from WKY and SHR rats. [Ca2+]i increase 
(maximal value at the peak, (A) and [Ca2+]i transient decay time (B) in WKY and SHR 
RCEs. SNAP (100 µM), L-NAME (10 µM) or W1400 (1 µM) were incubated 20 min before 
the administration of AT-II (1 µM). Values are the mean (±S.E.M.) of data from three 
separate RCE cell isolations, where at least 20–24 cells for each type of protocol were 
separately analyzed. Segments on the top of bars indicate significance between WKY and 
SHR; stars indicate significance between treatment and control, same strain: *** p < 0.001; 
** p < 0.01. 
The data depicted in Figure 2 were also reported in Table 1 as differences (Delta) between the calcium 
transient parameters in control (basal) and incubated cells with SNAP, W1400 or L-NAME.  
Table 1. Differences among control and incubated cells with the specified molecules in basal 
control in RCEs isolated from WKY and SHR after AT-II activation of calcium transient.  
 Delta [Ca2+]i (nM) 
 WKY SHR 
Control (basal) 0 0 
SNAP −430 −61 
W1400 +150 −137 
L-NAME +374 +106 
RLX-pretreated −223 +3 
 Delta Decay Time (s)
 WKY SHR 
Control (basal) 0 0 
SNAP −4.3  −2.1  
W1400 −0.7  −2.7  
L-NAME +5.2  −0.9  
RLX-pretreated −5 −1.9 
 
Control SNAP W1400 L-NAME
0
5
10
15
20
25
***
**
P<0.05
P<0.01
D
ec
ay
 ti
m
e 
(s
)
B
P<0.001
Control SNAP W1400 L-NAME
0
250
500
750
1000
1250
1500
1750
**
   
   
   
   
   
   
   
   
   
 [C
a2
+ ]
i (
nM
)
 WKY
 SHR
A
P<0.001
***
Molecules 2015, 20 9528 
 
 
The effect of RLX pretreatment is also reported. In WKY RCEs, maximal calcium values and decay 
times obtained were strongly reduced by SNAP and RLX, whereas L-NAME increased both parameters. 
W1400 only marginally influenced calcium transients, suggesting that under basal conditions the NO 
production was mainly dependent on the activation of a constitutive endothelial NOS. On the contrary, 
in SHR RCEs SNAP, NOS inhibition or RLX pretreatment were ineffective.  
2.2. Intracellular [Ca2+]: RLX Effects 
In WKY RCEs, a 24-h incubation with RLX decreased both peak and decay time of the  
agonist-induced [Ca2+]i transient (Figure 1A, Figure 3): the effect of RLX preincubation was potentiated 
by a 10-min. incubation with SNAP.  
A 20 min incubation with either the nonspecific NOS inhibitor L-NAME or the selective NOS II 
inhibitor 1400W modified the kinetics of AT-II induced [Ca2+]i transients in RLX-pretreated WKY 
RCEs: as shown, both inhibitors increased the maximum and the decay time of the calcium transient. A 
24 h incubation with RLX in SHR cells was ineffective in reducing the calcium transients, as evaluated 
by maximum values at the peak and decay times. Again, in SHR cells, the short incubation with SNAP 
or with both NOS inhibitors did not modify calcium transients in the RLX-pretreated cells. 
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Figure 3. Evaluation of [Ca2+]i in RCE isolated from WKY and SHR rats pretreated with 
RLX. [Ca2+]i increase (maximal value at the peak, (A) and [Ca2+]i transient decay time (B) 
in WKY and SHR RCEs. Cells were pretreated with RLX (60 ng/mL) for 24 h; SNAP  
(100 µM), L-NAME (10 µM) or W1400 (1 µM) were incubated 20 min. before the 
administration of AT-II (1 µM). Values are the mean (±S.E.M.) of data from three separate 
RCE cell isolations, where at least 20–24 cells for each type of protocols were analyzed 
separately. Segments on the top of bars indicate significance between WKY and SHR; stars 
indicate significance between treatment and control, same strain: *** p < 0.001; ** p < 0.01. 
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The effect of RLX pretreatment on the calcium transient induced by AT-II is reported in Table 2 as 
delta. In WKY, SNAP was still effective in reducing the maximal calcium value, while it influenced to 
a minimal extent decay time in RLX-pretreated cells. W1400 and L-NAME strongly increased calcium 
transient as indicated by the delta differences among in RLX-pretreated control and NOS inhibitors. The 
direct comparison of the alcium transient value of untreated cells shows that RLX effectively reduced 
the delta calcium and decay time value. On the contrary, in SHR RCEs RLX was ineffective and nor 
SNAP or NOS inhibition modified calcium transients.  
Table 2. Differences among control and incubated cells with the specified molecules  
in RLX-pretreated RCEs isolated from WKY and SHR after AT-II activation of  
calcium transient.  
 Delta [Ca2+]i (nM) 
 WKY SHR 
Control (RLX-pretreated) 0 0 
SNAP −281 −64 
W1400 +465 −104 
L-NAME +495 +204 
Control (basal) +223 −3 
 Delta Decay Time (s)
 WKY SHR 
Control (RLX-pretreated) 0 0 
SNAP −0.6 −0.4  
W1400 +6.3 −0.8  
L-NAME +5.8 −0.3  
Control (basal) +5 +1.9 
2.3. Effect of RLX on α-Thrombin-Induced Calcium Transient  
As already described [19], 30 U/mL THR induced a rise of [Ca2+]i in RCEs of both strains (Table 3). 
RLX pretreatment significantly reduced both parameters of calcium transient (i.e., maximal calcium 
peak and decay time) in WKY cells. Again, in SHR RCEs THR-induced calcium transients were not 
modified by RLX pretreatment (Table 3). 
Table 3. Effect of RLX-pretreatment (60 ng/mL) for 24 h) on 30 U/mL α-thrombin-induced 
calcium transient in coronary endothelial cells isolated from WKY and SHR rats. 
Control (basal) WKY SHR 
[Ca2+]i (Maximal value) 1820 ± 185.3 nM 1901 ± 178.6 nM 
Decay time 18.1 ± 0.83 s 19.0 ± 0.64 s 
24h RLX-Pretreated    
[Ca2+]i (Maximal value) 1168 ± 146.4 nM **, §§ 1841 ± 206.1 nM 
Decay time 13.4 ± 1.19 s ***, §§ 17.5 ± 2.03 s 
** p < 0.01 vs. WKY control, *** p < 0.001 vs. WKY control; §§ p < 0.01 vs. SHR RLX-pretreated. 
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2.4. NO Production in WKY and SHR Endothelial Cells Pretreated with Relaxin 
Accordingly to data already published [17], RLX increased NO production to 161% ± 17.2% (n = 3) 
in WKY and to 151% ± 21.3% (n = 3) in SHR RCEs as compared to controls (100%). 
3. Discussion 
The present data confirm that [Ca2+]i in RCEs isolated from normotensive WKY rats is strongly 
modulated by the NO pathway. In particular, while a NO donor decreases the calcium transient induced 
by AT-II, an aspecific inhibitor of NOS (L-NAME) can increase it. Moreover, the hormone RLX, known 
for its vasodilatory properties [5], reduces calcium transients in a NO-dependent mode related to NOS 
II [17]. These data validate the important role of NO in endothelial cells as a modulator of calcium 
signals in normotensive rats and suggest that NO can act in an autocrine manner in RCEs [12,17]. A 
remarkably different behavior is observed in SHR RCEs. In fact, in these cells, NO is unable to modulate 
[Ca2+]i and this ineffectiveness is maintained after treatment with RLX, suggesting that a downstream 
step of the NO pathway is altered. Similarly, using THR as calcium agonist, RLX-pretreatment strongly 
reduces calcium transients in WKY, whereas it is ineffective in SHR RCEs. Since RLX-pretreatment 
significantly lowers the calcium transients induced by two different agonists (i.e., AT-II and THR) only 
in WKY, the disfunctionality in SHR cells should lie in the NO pathway instead of the specific receptor 
signal. In this context, we have previously reported that SHR RCEs show low/absent expression of cGKI 
enzyme [12]. Moreover, a similar reduction of cGKI has been described in cardiomyocytes [11] and 
aortic smooth muscle cells [13]. The present data demonstrate that RLX is unable to restore NO 
responsiveness in SHR RCEs and appears to be partially in disagreement with previous in vivo studies 
in which RLX reduced blood pressure [14], cardiac and renal fibrosis [21] in SHR. This discrepancy 
may depend on many reasons. Multiple signal transduction pathways are activated in response to relaxin [6]. 
Indeed, RLX receptors are coupled with different G proteins, including the Gs cyclic AMP-stimulating 
protein [22]. Therefore in vivo effects of RLX in SHR could be mediated by other pathways. Of note, a 
direct NO-mediated relaxant effect of RLX on smooth musculature has been consistently described in 
other target organs, including smooth muscle cells [23], the uterus [24,25] and the gastrointestinal tract [26]. 
The current study evidences that RLX cannot restore NO responsiveness in SHR RCEs and underlines 
the importance of the NO/sGK/cGKI pathway in controlling the [Ca2+]i dynamics presiding to the 
regulation of vascular tone. 
A genome-wide association study found that common genetic polymorphisms in human cGKI-1 gene 
(PRKG1) are significantly associated with enhanced diastolic blood pressure in response to an acute salt 
load in patients with hypertension [27]. Chronically elevated blood pressure increases left ventricular 
(LV) pressure, enhances LV radial systolic performance and leads to LV hypertrophy. Recently, LV 
systolic radial deformation (strain) has been associated with common polymorphisms in PRKG1 [28]. 
In particular, LV radial systolic deformation is significantly higher in patients carrying PRKG1 
homozygote polymorphism than in heterozygotes and noncarriers. This knowledge may have clinical 
implications, as it suggests that NO-modulating drugs (including RLX) used for cardiovascular diseases 
might be low effective or ineffective in these patients. Even if further studies must be undertaken to 
elucidate how the genetic variants of PRKG1 might influence cardiovascular diseases, in homozygote 
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PRKG1 polymorphisms carriers, RLX could be ineffective in the treatment of hypertension and 
hypertensive heart diseases, suggesting an accurate evaluation of RLX effect in clinical setting. 
4. Experimental Section 
4.1. Chemicals 
Highly purified porcine RLX (2500–3000 U/mg) was a generous gift from O. D. Sherwood. RLX 
was used at a concentration of 60 ng/mL, which is in the range found effective in inducing coronary 
vasodilatation in rat hearts [29]. Media, sera, and reagents for cell culture were from Sigma-Aldrich 
(Milan, Italy) and Gibco Life Technologies (Milan, Italy). Cell culture plastic ware was purchased from 
Costar (Corning Costar Co., Costar Italia, Milan, Italy). Fura 2-AM and Pluronic F127 were from 
Molecular Probes Life Technologies (Milan, Italy). The selective NOS II inhibitor 1400W [30] was from 
Alexis Biochemicals (Enzo Life Sciences, New York, USA) and the NO-donor S-nitroso-N-
acetylpenicillamine (SNAP) from Tocris (Bristol, UK). THR was from Roche Life Sciences, NG-nitro-
L-arginine methylester (L-NAME) and angiotensin II (AT II) were from from Sigma-Aldrich as were 
the other chemicals used. 
4.2. Isolation and Culture of Rat Coronary Endothelial (RCE) Cells 
RCEs were isolated from the heart of 3–4-month old male Wistar Kyoto and aged matched SHR rats, 
as described previously [19]. Rats (Charles River, Lecco, Italy) were housed in the Centro per la 
Stabulazione degli Animali da Laboratorio (Ce.S.A.L., University of Florence), maintained for at least 
one week after their arrival in a 12 h dark-light cycle with pellet food and water ad libitum. Formal 
approval to conduct the experiments described was obtained from the Animal Subjects Review Board 
of the University of Florence. The ethics policy of the University of Florence complies with the Guide 
for the Care and Use of Laboratory Animals of the U.S. National Institutes of Health (NIH Publication 
No. 85-23, revised 1996; University of Florence Assurance No. A5278-01).  
Briefly, after enzymatic digestion of the heart, the suspension was centrifuged and the pellet was 
stirred for 30 min at 37 °C in the presence of 10 mg/50 mL trypsin. The recovered pellet was resuspended 
in 15 mL of culture medium (see below), and plated. After 4 h, cells were washed twice and grown until 
confluence (5–6 days) in M199 containing 10% fetal calf serum (FCS), 10% newborn calf serum, 250 U/mL 
penicillin G, 0.625 µg/mL amphotericin, and 250 µg/mL streptomycin. Isolated RCEs were 
cytocharacterized as previously reported [19,31]. Cells immunoreactive for endothelial markers ranged 
between 96% and 98%. For all experiments, cells were used at the first passage. Stimulation of RCEs 
with RLX was carried out in M199 medium without phenol red. 
4.3. Determination of Intracellular Ca2+ 
Intracellular cytosolic Ca2+ ([Ca2+]i) was evaluated with Fura-2 by microscopic image analysis as 
described previously [12,19]. Briefly, cells were grown on round cover slips to subconfluence and then 
incubated for 24 h in serum-free medium in the absence (controls) or presence of RLX (60 ng/mL). Cells 
were loaded with the Ca2+-sensitive fluorescent probe Fura 2-AM (4 µmol/L) and Pluronic F (0.02%) 
for 45 min at room temperature in HEPES-bicarbonate buffer containing (mM): NaCl 140, KCl 2.9, 
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NaH2PO4 0.5, NaHCO3 12, MgCl2 0.9, HEPES 10, CaCl2 1, glucose 10, adjusting pH to 7.4 with NaOH 
1 N. 
Coverslips were washed and mounted in the stage of an epifluorescence inverted microscopy in a 
perfusion chamber warmed at 35 °C. [Ca2+]i was measured dynamically by monitoring Fura-2 
fluorescence ratio. Consecutive images, obtained with excitation wavelengths of 340 and 380 nm and 
an emission wavelength of 510 nm, were recorded with a charge coupled device (CCD) video camera 
and digitized by an analogical/digital converter (resolution: 256 × 256 pixels, time interval between 
subsequent images: 800 ms). Image ratios (340/380 nm) were obtained every 3 s on a pixel-to-pixel 
basis after subtraction of the background.  
After measurements of [Ca2+]i in basal conditions, 1 µM AT II or 30 U/mL of THR were added 
directly into the perfusion chamber, and the time course of [Ca2+]i increase induced by agonists was 
analyzed for at least 15 min as already described [12,19]. A noise/signal ratio of 0.5 of 340/380 nm 
fluorescence was considered as the lowest detectable limit for [Ca2+]i transient. In some experiments, 
100 μM SNAP, the broad-spectrum NOS inhibitor L-NAME (10 µM) or the specific NOS II inhibitor 
1400W (1 µM) were added to the perfusion chamber 20 min before the addition of the agonist. 
Calibration curves were performed using a Kd of 214 nM for Fura-2. 
The experimental data were exported as ASCII file format and graphically elaborated with MicroCal 
Origin 9 software (OriginLab, Northhampton, MA, USA). The decay time of calcium transient was 
calculated as reported previously [19] and expressed as the time (s) needed for fluorescence ratio to 
reach 36.79% of the maximal value. The reported values are the mean (±SE) of data from three separate 
RCE cell isolations, where at least 20–24 cells for each type of protocols were analyzed separately. 
NO production was evaluated in the medium of control and 24h RLX pretreated cells by measuring 
nitrite production with Griess reagent as already described [17]. 
4.4. Calculations and Statistical Analysis 
Statistical comparisons were performed by using one-way ANOVA test followed by Student-Newman-
Keuls multiple comparison test. A p value ≤ 0.05 was considered as the low level of significance. 
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